Mats Wahlstrom Sells 99,988 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) Stock

Coherus BioSciences, Inc. (NASDAQ:CHRS - Get Free Report) Director Mats Wahlstrom sold 99,988 shares of the business's stock in a transaction dated Friday, May 23rd. The shares were sold at an average price of $0.74, for a total value of $73,991.12. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Coherus BioSciences Stock Performance

Shares of CHRS stock traded down $0.03 during trading hours on Friday, hitting $0.78. The company had a trading volume of 748,914 shares, compared to its average volume of 2,705,087. Coherus BioSciences, Inc. has a 12 month low of $0.66 and a 12 month high of $2.43. The firm has a market capitalization of $89.94 million, a price-to-earnings ratio of -9.70 and a beta of 1.01. The firm's fifty day moving average is $0.90 and its 200 day moving average is $1.13.

Coherus BioSciences (NASDAQ:CHRS - Get Free Report) last announced its earnings results on Monday, May 12th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.04). The firm had revenue of $7.60 million during the quarter, compared to analyst estimates of $59.79 million. During the same quarter in the prior year, the firm earned ($0.32) earnings per share. On average, sell-side analysts expect that Coherus BioSciences, Inc. will post -1.05 EPS for the current fiscal year.

Analyst Ratings Changes

CHRS has been the topic of several research reports. Wall Street Zen lowered Coherus BioSciences from a "hold" rating to a "sell" rating in a research note on Tuesday, May 20th. HC Wainwright reiterated a "buy" rating and issued a $7.00 price objective on shares of Coherus BioSciences in a research note on Tuesday, April 29th. Finally, UBS Group reiterated a "neutral" rating and issued a $1.05 price objective (down from $1.50) on shares of Coherus BioSciences in a research note on Thursday, April 24th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. boosted its holdings in shares of Coherus BioSciences by 1.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 976,857 shares of the biotechnology company's stock worth $1,348,000 after acquiring an additional 12,530 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Coherus BioSciences by 32.4% in the 4th quarter. Wells Fargo & Company MN now owns 61,830 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 15,137 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Coherus BioSciences by 97.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 30,847 shares of the biotechnology company's stock worth $43,000 after acquiring an additional 15,214 shares in the last quarter. CWM LLC boosted its holdings in shares of Coherus BioSciences by 96.6% in the 1st quarter. CWM LLC now owns 49,793 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 24,468 shares in the last quarter. Finally, Bank of Montreal Can acquired a new position in shares of Coherus BioSciences in the 4th quarter worth approximately $34,000. 72.82% of the stock is owned by institutional investors and hedge funds.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.